Off Patent
May 2026

Gattex Kit

teduglutide

Takeda Pharmaceuticals USA Inc

Powder (subcutaneous) · NDA 203441

Last listed protection ended
May 16, 2026

The FDA listed 2 patents and 1 exclusivity for Gattex Kit, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 7,847,061
    Claims a use (U-1320)
  2. Ended
    Patent 9,060,992
    Claims a use (U-1320)
  3. Ended
    Patent 7,847,061
    Pediatric extension: six more months
  4. Ended
    Patent 9,060,992
    Pediatric extension: six more months
  5. Ended
    Orphan drug exclusivity
    FDA code ODE-240